Phase 4 N=19 Stereotactic Body Radiotherapy for Head and Neck Tumors
Squamous Cell Carcinoma of the Head and Neck · Nasopharyngeal Carcinoma · Salivary Gland Cancer
Primary: Local Control Rate — 1; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Parotid Neoplasm · Thyroid Neoplasms · Head and Neck Neoplasms
Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
Phase 2 N=72 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Phase 2 N=21 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Phase 2 N=60 Treatment of Head & Neck Cancer With Chemotherapy and Radiation
Head and Neck Cancer
Primary: Two-Year Progression Free Survival (PFS) Probability, the Percentage of Patients Estimated to be Alive Without Worsening of Their Disease Two Years After Beginning…
N/A N=25 Low-Level Laser in Head and Neck Chronic Lymphedema
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Total Severity of External Lymphedema and Fibrosis (LEF) — 5.42; 4.08; 3.22; 4.62 score on a scale
N/A N=23 A Study Using Cone Beam CT for Head and Neck Cancer
Head and Neck Cancer
Primary: Rate of Movement of Normal Tissue
N/A N=12 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Duration of Local Control — 4.6 number of months to local failure
Phase 2 N=34 Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
Oropharyngeal Squamous Cell Cancer
Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale
N/A N=18 Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers
Resectable Head and Neck Squamous Cell Carcinoma
Primary: Maximum-tolerated Radiation Dose — 32.5 Gy
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=67 INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy
Head and Neck Squamous Cell Carcinoma
Primary: Risk of Solitary Elective Volume Recurrence Following Elective Volume Reduction Using INRT — 11; 9; 3; 6 percentage of participants
N/A N=12 Physiological Flow of Liquids in Head and Neck Cancer Patients: A Pilot Study
Deglutition Disorders · Oropharynx Cancer
Primary: Number of Participants With Unsafe Swallowing — 9; 4; 3 Participants
N/A N=170 Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery
Head and Neck Cancer · Oropharyngeal Cancer · Hypopharyngeal Cancer
Primary: Number of Participants With Adequate Exposure and Access to Oropharyngeal and Hypopharyngeal Head and Neck Lesions — 147; 23 participants
Phase 2 N=22 Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria — 6.7; 0 percentage of participants
Phase 2 N=3 Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
Carcinoma, Squamous Cell of Head and Neck
Primary: Number of Participants With Response — 0 Participants
Phase 2 N=113 PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Primary: Progression Free Survival (PFS) During the First-line Treatment Phase — 6.9; 5.5 Months — p=0.051
Phase 2 N=33 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Head and Neck Cancer · Cancer of the Pharynx · Cancer of the Larynx
Primary: Llocoregional Recurrence — 27 Participants
N/A N=18 Image Guided Adaptive Radiotherapy in the Head-and-neck Region
Head and Neck Neoplasms
Primary: Planning Target Volume (PTV) Coverage Parameter D98% — 7 participants
Phase 2 N=44 Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Head and Neck Cancer
Primary: Progression-free Survival at 2 Years — 75.9 percentage of participants
N/A N=80 Optimized Intensity Modulated Irradiation for Head and Neck Cancer
Head and Neck Cancer
Primary: Percentage of Participants With Grade 0-1 Observer-rated Dysphagia — 94 percentage of participants
N/A N=53 Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings - Optimization Phase
Head and Neck Cancer · Oral Cancer
Primary: Number of Participant Exams in Which Providers Reported the FNS (Flexible Nasopharyngoscope) is Easy to Use — 0; 9; 33; 6 Participant exams
Phase 2 N=3 Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Head and Neck Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck (SCCHN) · Head and Neck Cancer
Primary: Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800 — 10; 5; 3; NA Lymph nodes
N/A N=80 A Web-Based Multimedia Intervention for Head and Neck Cancer Patients
Cancer of the Head and Neck
Primary: Patient Distress — 66.16 units on a scale
Phase 2 N=39 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
N/A N=56 High Flow vs Conventional Oxygen in Head and Neck Surgery
Pulmonary Disease
Primary: Proportion of Patients With Post-operative Pulmonary Complication — 2; 11 Participants
N/A N=35 Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer
Caregiver · Malignant Head and Neck Neoplasm · Paranasal Sinus Squamous Cell Carcinoma
Primary: Number of Participants Noting Quite a Bit/Very Much Helpful to Survey Questions — 4; 6; 7; 6 Participants
Phase 4 N=100 Regional Block for Postoperative Free Flap Care
Pain Management
Primary: Opioid Utilization Measured in Oral Morphine Equivalent (OME) — 118; 166 mg
Phase 3 N=145 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
Head and Neck Cancer
Primary: Overall Survival — 73; 78 percent of patients